Tag Archives: NHS

Value-Based Assessment in the UK: The Industry View

By Leela Barham. In the UK, Value-Based Pricing (VBP) has morphed into Value-Based Assessment (VBA), with the National Institute for Health and Care Excellence (NICE) tasked with taking the loose policy concepts (established as far back as 2010) and actually implementing them. Earlier this year, NICE set out its approach, which boiled down to taking a […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , , , | Leave a comment

Show Me the Money: First New PPRS Payments in UK

By Leela Barham. The Pharmaceutical Price Regulation Scheme (PPRS) is a long-standing scheme where the pharmaceutical industry, represented by the Association of the British Pharmaceutical Industry (ABPI), negotiates with the Department of Health (DH) to agree how to indirectly manage the price of branded medicines. Its latest incarnation includes a brand new feature. Instead of […]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Also tagged , , , | Leave a comment

England: Ignoring NICE Guidelines Can Be Unlawful

By Leela Barham. An administrative court has said that a Clinical Commission Group (CCG, a local budget holder for the National Health Service in England) can’t just disagree with guidance from the UK’s National Institute for Health and Clinical Excellence (NICE) — that’s unlawful.
Posted in Europe, Guest Blog, pricing, Regulatory | Also tagged , , , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

UK Drug Pricing: An ICER of Zero?

by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
Posted in Europe, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta